fablyn
dr. friedrich eberth arzneimittel gmbh - lasofoxifene tartrat - osteoporose, postmenopausale - køn hormoner og modulatorer af den genitale system, - fablyn er indiceret til behandling af osteoporose hos postmenopausale kvinder med øget risiko for fraktur. der er vist en signifikant reduktion i forekomsten af vertebrale og ikke-vertebrale frakturer, men ikke hoftefrakturer (se afsnit 5. når du bestemme valg af fablyn eller andre behandlingsformer, herunder østrogener, til postmenopausale kvinde, bør det overvejes, menopausale symptomer, effekter på livmoder og bryst væv, og hjerte-kar-risici og fordele (se afsnit 5.
daltex 50+1000 mg filmovertrukne tabletter
medochemie ltd. - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+1000 mg
vildagliptin/metformin "aet" 50+1000 mg filmovertrukne tabletter
tiefenbacher gmbh - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+1000 mg
venofer 20 mg/ml injektionsvæske/konc. til infusionsvæske, opløsning
vifor france - jernsaccharose - injektionsvæske/konc. til infusionsvæske, opløsning - 20 mg/ml
ferinject 50 mg/ml injektions-/infusionsvæske, dispersion
vifor france - ferricarboxymaltose - injektions-/infusionsvæske, dispersion - 50 mg/ml
velphoro
vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - lægemidler til behandling af hyperkaliæmi og hyperphosphatemia - velphoro er indiceret til kontrol af serumfosforniveauer hos patienter med kronisk nyresygdom (ckd) hos patienter med hæmodialyse (hd) eller peritonealdialyse (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.
rayaldee 30 mikrogram depotkapsler, bløde
vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - alle andre terapeutiske produkter - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
tysabri
biogen netherlands b.v. - natalizumab - multipel sclerose - selektive immunosuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.